Showing results (151-160 of 180) with videos related to
Sort By:
Pageof 18
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.Leukemia|February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomesThierry Facon, Philippe Moreau, Katja Weisel, et al.Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A Walker, Eileen M Boyle, Christopher P Wardell, et al.Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.Pageof 18